Shanghai SciBrunch Therapeutics

Shanghai SciBrunch Therapeutics is a clinical-stage biotechnology company based in Shanghai, China, dedicated to the iterative innovation of small molecule therapeutics for oncology. Founded in 2024 by experienced entrepreneurs Dr. Tao Hu and Dr. Yang Zhang, the company leverages a differentiated design approach to develop next-generation treatments for clinically validated targets. Its lead program, SPR1020, is a highly selective and brain-penetrant PARP1 inhibitor currently undergoing Phase 1 clinical evaluation for advanced solid tumors, including breast and ovarian cancers. The company is also advancing a pipeline of molecular glue-based RAS inhibitors and brain-penetrant RTK inhibitors aimed at addressing refractory tumors with high unmet needs. SciBrunch has secured significant backing from investors such as HighLight Capital and InnoPinnacle Fund to support its mission of creating globally competitive cancer therapies.